Litcius/Paper detail

A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanoma

Maria Brambati, Chiara Giuffré, Alessandro Marchese, Francesco Bandello, Giulio Modorati, Elisabetta Miserocchi

2020European Journal of Ophthalmology26 citationsDOI

Abstract

We report a case of ocular drug toxicity consistent with bilateral Vogt-Koyanagi-Harada (VKH) like disease in a patient with cutaneous melanoma treated with Dabrafenib/Trametinib therapy. A 53-year-old man with a history of metastatic cutaneous melanoma, treated with Dabrafenib/Trametinib, developed a severe acute panuveitis with granulomatous anterior uveitis and multiple serous retinal detachments. The ocular inflammatory reaction was classified as a bilateral Vogt-Koyanagi-Harada disease. Intraocular inflammation resolved after discontinuation of chemotherapeutic agents and aggressive topical and systemic corticosteroid therapy. The present case outlines the importance of recognizing VKH-like syndrome as a possible consequence of therapy with dabrafenib and trametinib.

Topics & Concepts

DabrafenibTrametinibMedicineUveitisDermatologyDiscontinuationMelanomaDacarbazineSurgeryVemurafenibOphthalmologyCancer researchMAPK/ERK pathwayMetastatic melanomaKinaseCell biologyBiologyMelanoma and MAPK PathwaysMultiple Myeloma Research and TreatmentsOcular Diseases and Behçet’s Syndrome
A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanoma | Litcius